Advanced

A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer

Rose, Carsten LU (2003) In American Journal of Clinical Oncology 26(4 Suppl.1). p.9-16
Abstract
Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy. Significant gains in clinical efficacy and improved tolerability over progestins (megestrol acetate) and the first-generation AI aminoglutethimide have positioned these agents above previous therapies. Estrogen receptor (ER) status remains the best predictive determinant of endocrine response, and further randomized trials with properly selected patient populations may distinguish individual AIs within this class. A recently completed, randomized.... (More)
Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy. Significant gains in clinical efficacy and improved tolerability over progestins (megestrol acetate) and the first-generation AI aminoglutethimide have positioned these agents above previous therapies. Estrogen receptor (ER) status remains the best predictive determinant of endocrine response, and further randomized trials with properly selected patient populations may distinguish individual AIs within this class. A recently completed, randomized. head-to-head phase III trial of letrozole versus anastrozole as second-line endocrine therapy demonstrated a significant difference in objective response rate for letrozole compared with anastrozole (19% versus 12%, respectively; P = 0.014), with similar time to progression. The improved efficacy and safety of AIs as second-line endocrine therapies has spawned trials of their use as first-line endocrine therapy versus tamoxifen for patients with metastatic breast cancer. Based on favorable results from these trials, letrozole and anastrozole have also been approved for use as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
second-line therapy, therapy, first-line, estrogen receptor, aromatase inhibitors, breast cancer
in
American Journal of Clinical Oncology
volume
26
issue
4 Suppl.1
pages
9 - 16
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000184783400003
  • pmid:12902872
  • scopus:0043092398
ISSN
0277-3732
language
English
LU publication?
yes
id
ede4c2d2-60ae-402c-b861-7cf8e6f51371 (old id 304095)
date added to LUP
2007-09-20 18:27:43
date last changed
2018-05-29 11:58:24
@article{ede4c2d2-60ae-402c-b861-7cf8e6f51371,
  abstract     = {Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy. Significant gains in clinical efficacy and improved tolerability over progestins (megestrol acetate) and the first-generation AI aminoglutethimide have positioned these agents above previous therapies. Estrogen receptor (ER) status remains the best predictive determinant of endocrine response, and further randomized trials with properly selected patient populations may distinguish individual AIs within this class. A recently completed, randomized. head-to-head phase III trial of letrozole versus anastrozole as second-line endocrine therapy demonstrated a significant difference in objective response rate for letrozole compared with anastrozole (19% versus 12%, respectively; P = 0.014), with similar time to progression. The improved efficacy and safety of AIs as second-line endocrine therapies has spawned trials of their use as first-line endocrine therapy versus tamoxifen for patients with metastatic breast cancer. Based on favorable results from these trials, letrozole and anastrozole have also been approved for use as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer.},
  author       = {Rose, Carsten},
  issn         = {0277-3732},
  keyword      = {second-line therapy,therapy,first-line,estrogen receptor,aromatase inhibitors,breast cancer},
  language     = {eng},
  number       = {4 Suppl.1},
  pages        = {9--16},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {American Journal of Clinical Oncology},
  title        = {A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer},
  volume       = {26},
  year         = {2003},
}